How Three Experimental Antibiotics Attack Tuberculosis - Each in a Different Way

Tuberculosis killed approximately 1.2 million people in 2023, making it one of the deadliest infectious diseases in the world. The rise of drug-resistant strains - strains that survive the antibiotics that were once reliable - has made the search for new treatment approaches a genuine priority. Three naturally occurring compounds have attracted attention as candidates for a new class of TB drugs. A study published in Nature Communications from the University of Sydney and the Centenary Institute now reveals precisely how they work - and why their mechanisms matter for understanding resistance.

The compounds are ecumicin, ilamycin, and cyclomarin. All three were known to kill Mycobacterium tuberculosis, the bacterium responsible for TB, but the molecular details of how they did so had not been fully characterized. The new study fills that gap, and what it found was more complex than anticipated.

A molecular machine the bacterium cannot survive without

All three compounds target the same molecular complex inside the TB bacterium: the ClpC1-ClpP1P2 protease system. This is essentially the bacterium's cellular garbage disposal - a molecular machine that breaks down damaged, misfolded, or surplus proteins and recycles their components. Without it, the bacterium cannot manage the protein quality control needed to survive stress conditions, particularly the hostile environment inside an infected human body.

The complex has two main components. ClpC1 is the AAA+ ATPase - the engine that recognizes and unfolds target proteins, using energy from ATP hydrolysis. ClpP1P2 is the protease barrel where the actual degradation occurs. Together, they form a system that is essential for bacterial viability and has no direct equivalent in human cells, making it an attractive drug target because inhibiting it should, in principle, harm the bacterium without harming the patient.

Three mechanisms, not one

The key finding is that the three antibiotics do not work the same way, even though they all target the same complex. Using a combination of biochemical assays, structural analysis, and metabolomic profiling, the research team characterized how each compound interacts with ClpC1 and how each interaction disrupts the system differently.

Ecumicin and ilamycin both bind to ClpC1, but they shift the protein into different conformational states - different three-dimensional shapes that alter how it functions. Cyclomarin binds to a different region of ClpC1 altogether. Each binding mode leads to dysregulation of the ClpC1-ClpP1P2 complex, but the downstream consequences for the bacterium's metabolism differ between compounds.

First author Isabel Barter, a PhD candidate at the University of Sydney who conducted part of the research at the Centenary Institute, described the result as revealing surprising complexity in how these compounds affect the system. Rather than simply shutting it down, each compound triggers a distinct pattern of imbalance. The metabolomic data showed that these different disruptions ripple outward into different parts of the bacterium's biochemistry, affecting processes beyond protein degradation.

Why distinct mechanisms matter for drug resistance

Co-senior author Professor Warwick Britton from the Centenary Institute's Centre for Infection and Immunity emphasized the significance of having three different mechanisms targeting the same essential complex. If a bacterium develops resistance to one compound by mutating the binding site that compound uses, the other two compounds - which bind elsewhere - may remain effective. This is the principle behind combination therapy, and it applies with particular force to TB, where resistance develops through mutation and spreads efficiently.

Drug-resistant TB strains, including multi-drug-resistant TB and extensively drug-resistant TB, already pose treatment challenges that current regimens struggle to address. New compounds with novel mechanisms offer the possibility of reaching strains that existing drugs cannot.

From mechanism to medicine - a long road ahead

The study characterizes mechanisms at the molecular level. It does not demonstrate efficacy in animal models, and it does not address the pharmacokinetic questions - absorption, distribution, metabolism, and excretion - that determine whether a compound can function as a drug in a living organism. These are substantial hurdles. Many compounds that kill bacteria in laboratory conditions fail at later stages because they cannot reach the target in sufficient concentrations, degrade too quickly, or cause unacceptable side effects.

The Asia-Pacific region bears a disproportionate share of the global TB burden, and the researchers note the particular urgency of developing new treatments for that context. Understanding the mechanistic differences between these three compounds provides a framework for designing derivatives that might improve on their limitations - better binding, greater potency, or more favorable pharmacokinetics.

What the study establishes is that three promising antibiotic candidates each have distinct, characterizable modes of action against a high-priority target in TB. That mechanistic clarity is the necessary starting point for the optimization work that would eventually need to happen before any of them could become a clinical drug.